Lee Christine U, Larson Nicholas B, Urban Matthew W, Miller A Lee, Uthamaraj Susheil, Piltin Mara A, Jakub James W, Bhatt Asha A, Greenleaf James F, Hesley Gina K
Department of Radiology, Division of Breast Imaging and Intervention, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
AJR Am J Roentgenol. 2023 Mar;220(3):358-370. doi: 10.2214/AJR.22.28107. Epub 2022 Aug 31.
Targeted axillary lymph node dissection after neoadjuvant systemic therapy (NST) for breast cancer depends on identifying marked metastatic lymph nodes. However, ultrasound visualization of biopsy markers is challenging. The purpose of our study was to identify biopsy markers that show actionable twinkling in cadaveric breast and to assess the association of actionable twinkling with markers' surface roughness. Commercial breast biopsy markers were evaluated for twinkling artifact in various experimental conditions relating to scanning medium (solid gel phantom, ultrasound coupling gel, cadaveric breast), transducer (ML6-15, 9L, C1-6), and embedding material (present vs absent). Markers were assigned twinkling scores from 0 (confident in no twinkling) to 4 (confident in exuberant twinkling); a score of 3 or greater represented actionable twinkling (sufficient confidence to rely solely on twinkling for target localization). Markers were hierarchically advanced to evaluation with increasingly complex media if showing at least minimal twinkling for a given medium. A 3D coherence optical profiler measured marker surface roughness. Mixed-effects proportional odds regression models assessed associations between twinkling scores and transducer and embedding material; Wilcoxon rank sum test evaluated associations between actionable twinkling and surface roughness. Thirty-five markers (21 with embedding material) were evaluated. Ten markers without embedding material advanced to evaluation in cadaveric breast. Higher twinkling scores were associated with presence of embedding material (odds ratio [OR] = 5.05 in solid gel phantom, 9.84 in coupling gel) and transducer (using the C1-6 transducer as reference; 9L transducer: OR = 0.36, 0.83, and 0.04 in solid gel phantom, ultrasound coupling gel, and cadaveric breast; ML6-15 transducer: OR = 0.07, 0.18, and 0.00 respectively; post hoc between 9L and ML6-15: < .001, = .02, and = .04). In cadaveric breast, three markers (Cork, Professional Q, MRI [Flex]) exhibited actionable twinkling for two or more transducers; surface roughness was significantly higher for markers with than without actionable twinkling for C1-6 (median values: 0.97 vs 0.35, = .02) and 9L (1.75 vs 0.36; = .002) transducers. Certain breast biopsy markers exhibited actionable twinkling in cadaveric breast. Twinkling was observed with greater confidence for the C1-6 and 9L transducers than the ML6-15 transducer. Actionable twinkling was associated with higher marker surface roughness. Use of twinkling for marker detection could impact preoperative or intraoperative localization after NST.
乳腺癌新辅助全身治疗(NST)后的靶向腋窝淋巴结清扫取决于识别有明显转移的淋巴结。然而,活检标记物的超声可视化具有挑战性。我们研究的目的是识别在尸体乳房中显示可用于操作的闪烁的活检标记物,并评估可用于操作的闪烁与标记物表面粗糙度之间的关联。在与扫描介质(固体凝胶体模、超声耦合凝胶、尸体乳房)、换能器(ML6-15、9L、C1-6)和包埋材料(存在与否)相关的各种实验条件下,对商用乳房活检标记物的闪烁伪像进行评估。标记物的闪烁评分从0(确定无闪烁)到4(确定闪烁强烈);3分或更高的评分表示可用于操作的闪烁(有足够信心仅依靠闪烁进行靶点定位)。如果在给定介质中显示至少最小程度的闪烁,则标记物会逐步进入使用越来越复杂介质的评估。三维相干光学轮廓仪测量标记物表面粗糙度。混合效应比例优势回归模型评估闪烁评分与换能器和包埋材料之间的关联;Wilcoxon秩和检验评估可用于操作的闪烁与表面粗糙度之间的关联。评估了35个标记物(21个带有包埋材料)。10个没有包埋材料的标记物进入尸体乳房评估。较高的闪烁评分与包埋材料的存在(在固体凝胶体模中的优势比[OR]=5.05,在耦合凝胶中的优势比=9.84)和换能器有关(以C1-6换能器为参照;9L换能器:在固体凝胶体模、超声耦合凝胶和尸体乳房中的OR分别为0.36、0.83和0.04;ML6-15换能器:分别为0.07、0.18和0.00;事后检验9L和ML6-15之间:<.001、=.02和=.04)。在尸体乳房中,三种标记物(软木塞、专业Q、MRI[Flex])对两种或更多换能器表现出可用于操作的闪烁;对于C1-6(中位数:0.97对0.35,=.02)和9L(1.75对0.36;=.002)换能器,有可用于操作的闪烁的标记物的表面粗糙度显著高于没有可用于操作的闪烁的标记物。某些乳房活检标记物在尸体乳房中表现出可用于操作的闪烁。与ML6-15换能器相比,使用C1-6和9L换能器观察到闪烁的信心更强。可用于操作的闪烁与更高的标记物表面粗糙度相关。利用闪烁进行标记物检测可能会影响NST后的术前或术中定位。